Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 3/20 | 0.48 |
| ▸ | CDK8 | P49336 | 3/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187370 | 0.89 | AKT1 (0.49) | CCNCCDK8ADRB2ADRB1ADRB3 | |
| SCHEMBL4199203 | 0.87 | CA12 (0.55) | ADRB2ADRB1ADRB3AKT1KIT | |
| SCHEMBL4199286 | 0.86 | PAK1 (0.50) | CCNCCDK8ADRB2ADRB1ADRB3 | |
| SCHEMBL4196118 | 0.86 | PAK1 (0.55) | ADRB2ADRB1ADRB3AKT1KIT | |
| SCHEMBL4202933 | 0.84 | KIT (0.47) | ADRB2ADRB1ADRB3KITPDGFRB | |
| SCHEMBL4194231 | 0.84 | KIT (0.49) | CCNCCDK8ADRB2ADRB1ADRB3 | |
| SCHEMBL4970207 | 0.84 | PDGFRB (0.67) | KITPDGFRBCSF1RFLT3KDR | |
| SCHEMBL4195893 | 0.83 | AKT1 (0.47) | CCNCCDK8ADRB2ADRB1ADRB3 | |
| SCHEMBL4198431 | 0.82 | KIT (0.52) | ADRB2ADRB1ADRB3KITPDGFRB | |
| SCHEMBL4192384 | 0.82 | GAA (0.53) | CCNCCDK8ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-04 | — | — | US | disclosed |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-04 | — | — | US | disclosed |
| EP-1893215-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135630-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281769-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060281768-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281768-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | CCNC 84/4885CDK8 274/4885ADRB2 3551/4885 |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | CCNC 84/4885CDK8 274/4885ADRB2 3551/4885 |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | CCNC 84/4885CDK8 274/4885ADRB2 3551/4885 |
| US-20060281769-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, TPX2 | CCNC 386/4885CDK8 740/4885ADRB2 4517/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | CCNC 563/4885CDK8 329/4885ADRB2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.